Clinical trial Recruiting at 1 site Phase 2 Interventional Ages 21 and up

Examining surgery and medications for obstructive sleep apnea

Official title: Endotypic Traits and Obstructive Sleep Apnea Surgery

Run by University of California, Los Angeles · NCT05953610 · Data updated 2026-11-12

This study is testing if soft palate surgery and certain medications can help people with moderate to severe obstructive sleep apnea who can't use a CPAP machine feel better and breathe easier.

Quick facts

PhasePhase 2
Study typeInterventional
Ages21 Years and up
SexAll
Enrollment150 (estimated)
SponsorUniversity of California, Los Angeles
Academic / other
Locations2 sites (Santa Monica, California and 1 other locations)
StatusRecruiting
StartedJanuary 7, 2024
Main results expectedAugust 31, 2028
Study endsAugust 31, 2028
Registry record updatedJuly 1, 2026
Trial IDNCT05953610 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are adults aged 21 and older with moderate to severe obstructive sleep apnea who are intolerant to positive airway pressure therapy.

Probably not a fit

Patients with uncontrolled nasal obstruction, significant psychiatric disorders, or other co-existing sleep disorders may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study investigates the outcomes of soft palate surgery and the effects of medications like acetazolamide and eszopiclone on patients with moderate to severe obstructive sleep apnea (OSA) who cannot tolerate positive airway pressure. It involves a cohort of 150 participants undergoing drug-induced sleep endoscopy to measure upper airway closing pressure and assess OSA severity before and six months after surgery. The study aims to identify underlying mechanisms of OSA and evaluate treatment efficacy through a randomized crossover design for those who do not achieve resolution of OSA post-surgery.

Why it matters

Potential benefit: If successful, this study could provide new treatment options for patients with obstructive sleep apnea who do not respond to conventional therapies.

How similar studies have gone: Other studies have shown promise in similar approaches, but this specific combination of interventions is relatively novel.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion criteria are:

1. age ≥21 years;
2. moderate to severe OSA (obstructive AHI ≥ 15 events/hour);
3. central/mixed apnea index \<5 events/hour;
4. intolerance of positive airway pressure (defined as use \< 2 hours/night at least 5 nights/week);
5. intolerance or poor candidate for oral appliance;
6. participant has provided informed consent for palate surgery as part of their standard of care;
7. tonsil size 0-2+ (without markedly enlarged tonsils that have high surgical success rates);
8. DISE without evidence of complete tongue-related obstruction (reflecting poorer results with isolated palate surgery);
9. medications stable for ≥2 months;
10. body mass index \<35 kg/m2;
11. absence of uncontrolled nasal obstruction;
12. no prior pharyngeal surgery other than tonsillectomy;
13. no neurologic, cardiac or pulmonary disorders;
14. absence of psychiatric disorder except for treated depression or mild anxiety;
15. no co-existing sleep disorder, such as narcolepsy, chronic insomnia, or restless legs syndrome;
16. no use of hypnotics, anxiolytics, stimulants, or sedating antidepressants;
17. no near-miss or prior motor vehicle crash due to sleepiness in past 12 months; and
18. \<3 caffeinated beverages daily.

Exclusion criteria are:

1. history of allergic reaction to either of the study drugs;
2. subjects with prior serious allergic reaction (such as Stevens-Johnson syndrome) to sulfonamides;
3. subjects with a history of hypersensitivity to either of the two study drugs;
4. subjects who are on high-dose aspirin therapy due to risk of severe metabolic acidosis;
5. subjects with severe kidney disease or severe liver disease;
6. subjects with a history of electrolyte imbalance or adrenal insufficiency (due to risks related to acetazolamide);
7. subjects on ketoconazole or other strong CYP3A4 inhibitors (these will increase eszopiclone blood levels);
8. pregnancy; and
9. alcohol or substance abuse.

Where it's running

  • UCLA Santa Monica Medical Center
    Santa Monica, California, United States
    Recruiting
  • UCLA Westwood
    Westwood, Los Angeles, California, United States
    Not yet recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.